Kalpit Patel
Stock Analyst at B. Riley Securities
(0.80)
# 3,984
Out of 5,044 analysts
59
Total ratings
30.23%
Success rate
-12.11%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Kalpit Patel
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| DERM Journey Medical | Maintains: Buy | $9 → $12 | $8.13 | +47.60% | 6 | Jul 30, 2025 | |
| KYMR Kymera Therapeutics | Upgrades: Buy | $38 → $60 | $61.95 | -3.15% | 5 | Jun 3, 2025 | |
| BCYC Bicycle Therapeutics | Maintains: Neutral | $17 → $14 | $8.22 | +70.32% | 7 | May 2, 2025 | |
| AVBP ArriVent BioPharma | Initiates: Buy | $37 | $19.65 | +88.30% | 1 | Mar 20, 2025 | |
| RIGL Rigel Pharmaceuticals | Maintains: Neutral | $20 → $24 | $29.69 | -19.16% | 6 | Mar 5, 2025 | |
| GERN Geron | Maintains: Buy | $5.5 → $3.5 | $1.28 | +173.44% | 4 | Feb 18, 2025 | |
| VSTM Verastem | Maintains: Buy | $7 → $9 | $8.85 | +1.69% | 4 | Jan 31, 2025 | |
| FHTX Foghorn Therapeutics | Initiates: Buy | $10 | $4.45 | +124.72% | 1 | Jan 30, 2025 | |
| PDSB PDS Biotechnology | Maintains: Buy | $9 → $7 | $0.93 | +650.27% | 5 | Nov 25, 2024 | |
| CRBP Corbus Pharmaceuticals Holdings | Maintains: Buy | $85 → $40 | $17.12 | +133.64% | 2 | Sep 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $9 → $3 | $1.49 | +101.34% | 2 | Jun 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $25 → $20 | $23.17 | -13.68% | 3 | May 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $90 → $30 | $3.81 | +687.40% | 1 | Dec 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $34 → $36 | $13.51 | +166.47% | 2 | Jul 25, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $270 → $90 | $2.10 | +4,185.71% | 3 | Nov 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $21 → $18 | $1.26 | +1,328.57% | 2 | Sep 22, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $6 → $5 | $2.52 | +98.41% | 2 | Jul 19, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $240 → $100 | $14.20 | +604.47% | 1 | Jan 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $75 | $13.46 | +457.21% | 2 | Sep 3, 2021 |
Journey Medical
Jul 30, 2025
Maintains: Buy
Price Target: $9 → $12
Current: $8.13
Upside: +47.60%
Kymera Therapeutics
Jun 3, 2025
Upgrades: Buy
Price Target: $38 → $60
Current: $61.95
Upside: -3.15%
Bicycle Therapeutics
May 2, 2025
Maintains: Neutral
Price Target: $17 → $14
Current: $8.22
Upside: +70.32%
ArriVent BioPharma
Mar 20, 2025
Initiates: Buy
Price Target: $37
Current: $19.65
Upside: +88.30%
Rigel Pharmaceuticals
Mar 5, 2025
Maintains: Neutral
Price Target: $20 → $24
Current: $29.69
Upside: -19.16%
Geron
Feb 18, 2025
Maintains: Buy
Price Target: $5.5 → $3.5
Current: $1.28
Upside: +173.44%
Verastem
Jan 31, 2025
Maintains: Buy
Price Target: $7 → $9
Current: $8.85
Upside: +1.69%
Foghorn Therapeutics
Jan 30, 2025
Initiates: Buy
Price Target: $10
Current: $4.45
Upside: +124.72%
PDS Biotechnology
Nov 25, 2024
Maintains: Buy
Price Target: $9 → $7
Current: $0.93
Upside: +650.27%
Corbus Pharmaceuticals Holdings
Sep 20, 2024
Maintains: Buy
Price Target: $85 → $40
Current: $17.12
Upside: +133.64%
Jun 18, 2024
Maintains: Buy
Price Target: $9 → $3
Current: $1.49
Upside: +101.34%
May 9, 2024
Downgrades: Neutral
Price Target: $25 → $20
Current: $23.17
Upside: -13.68%
Dec 12, 2023
Downgrades: Neutral
Price Target: $90 → $30
Current: $3.81
Upside: +687.40%
Jul 25, 2023
Maintains: Buy
Price Target: $34 → $36
Current: $13.51
Upside: +166.47%
Nov 11, 2022
Downgrades: Neutral
Price Target: $270 → $90
Current: $2.10
Upside: +4,185.71%
Sep 22, 2022
Maintains: Buy
Price Target: $21 → $18
Current: $1.26
Upside: +1,328.57%
Jul 19, 2022
Maintains: Buy
Price Target: $6 → $5
Current: $2.52
Upside: +98.41%
Jan 24, 2022
Maintains: Buy
Price Target: $240 → $100
Current: $14.20
Upside: +604.47%
Sep 3, 2021
Downgrades: Neutral
Price Target: $75
Current: $13.46
Upside: +457.21%